Hormone Treatment, Does Timing Matter?

Elliott, William T.
May 2007
Travel Medicine Advisor;May2007, Vol. 17 Issue 5, p2
The article provides information on a study that suggested that women who initiated hormone therapy closer to menopause had a reduced risk of coronary heart disease. The research looked at postmenopausal women who had undergone a hysterectomy and were randomized to conjugated estrogen or placebo and women who had not had a hysterectomy who were randomized to conjugated estrogen plus medroxyprogesterone or placebo.


Related Articles

  • Which postmenopausal women should be offered combined HRT? Oliver, M. Norman; Sheufelt, Janice; Deshpande, Prajakta; Grandage, Karen K.; St. Anna, Leilani // Journal of Family Practice;Feb2003, Vol. 52 Issue 2, p149 

    The article talks about the adverse effects of hormone replacement therapy (HRT) on postmenopausal women including cardiovascular disease, thromboembolic disease and breast cancer. The Women's Health Initiative randomized trial of HRT on the use of estrogen plus progestin for prevention of...

  • Postmenopausal Hormone Use and Secondary Prevention of Coronary Events in the Nurses' Health Study. Grodstein, Francine; Manon, JoAnn E.; Stampfer, Meir J. // Annals of Internal Medicine;7/3/2001, Vol. 135 Issue 1, p1 

    Discusses results of a study on the effectiveness of postmenopausal hormone use in the secondary prevention of coronary events. Patient characteristics; Decreasing recurrence of major coronary heart disease events with increasing duration of hormone use; Absence of difference between users of...

  • Gender-based differences in mechanisms of protection in myocardial ischemia�reperfusion injury. Murphy, Elizabeth; Steenbergen, Charles // Cardiovascular Research;Aug2007, Vol. 75 Issue 3, p478 

    Abstract: Pre-menopausal women have reduced risk for cardiovascular disease, and cardiovascular disease rises after menopause. Studies in animal models have also suggested that females have reduced injury following ischemia and reperfusion (I/R). However, a large clinical trial, the Women''s...

  • Update on the benefits and risks of hormone replacement therapy. Wright, Letiita J.; Klanataridou, Sophia N.; Calis, Karim Anton // Formulary;Feb2002, Vol. 37 Issue 2, p78 

    Examines the risk and benefit of hormone replacement therapy in treating postmenopausal symptoms. Association of estrogen deficiency with development of hot flashes; Reduction of fracture rates; Positive effects on indicators of coronary heart disease in postmenopausal women. INSET: Abstract.

  • HRT does not prevent heart disease. Tanne, Janice Hopkins // BMJ: British Medical Journal (International Edition);8/16/2003, Vol. 327 Issue 7411, p359 

    Discusses how hormone replacement therapy (HRT) does not prevent coronary heart disease. Consideration of a medical trial that compared the combined estrogen and progestogen treatment with placebo; Risk of myocardial infarction and death in women who were given a placebo; Role of oestrogen in...

  • HRT and vitamins C and E do not improve coronary disease in women. Lutfiyya, M. Nawal; Henley, Eric // Journal of Family Practice;Feb2003, Vol. 52 Issue 2, p112 

    The article presents a study on the use of hormone replacement therapy (HRT) and antioxidant vitamin supplements E and C, on postmenopausal women with coronary heart disease. The study was conducted among postmenopausal women with coronary disease recruited from 7 clinical sites in the U.S. and...

  • Hormone replacement therapy and cardiovascular disease revisited. Stevenson, John C. // Menopause International;Jun2009, Vol. 15 Issue 2, p55 

    Controversy still rages about whether hormone replacement therapy (HRT) confers cardiovascular benefit or harm. There is a wealth of biological evidence that estrogen has a beneficial effect, supporting a large body of epidemiological evidence demonstrating reduction in coronary events with HRT....

  • Combined HRT increased CV events more than placebo but did not differ from oestrogen HRT after menopause.  // Evidence Based Medicine;Apr2008, Vol. 13 Issue 2, p52 

    STUDY DESIGN Design: randomised controlled trial (Women's International Study of long Duration Oestrogen after Menopause [WISDOM]) Allocation: concealed.* Blinding: blinded ({patients, healthcare providers}t, and outcome assessors).* Setting: 384 general practices in the UK, 91 in Australia, and...

  • Conjugated equine estrogens not associated with cardiovascular disease or breast cancer.  // Australian Journal of Pharmacy;Sep2011, Vol. 92 Issue 1096, p99 

    The article reports that conjugated equine estrogens (CEE) is not associated with stroke, coronary heart disease and breast cancer, in postmenopausal women with prior hysterectomy, according to a study. It states that the health outcomes were favorable for younger women as compared to older...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics